An open-label phase II study of low-dose thalidomide in androgen-independent prostate cancer

The antiangiogenic effects of thalidomide have been assessed in clinical trials in patients with various solid and haematological malignancies. Thalidomide blocks the activity of angiogenic agents including bFGF, VEGF and IL-6. We undertook an open-label study using thalidomide 100 mg once daily for...

Descripción completa

Detalles Bibliográficos
Autores principales: Drake, M J, Robson, W, Mehta, P, Schofield, I, Neal, D E, Leung, H Y
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2003
Materias:
Clinical
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2377091/
https://www.ncbi.nlm.nih.gov/pubmed/12644816
http://dx.doi.org/10.1038/sj.bjc.6600817

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2377091/
https://www.ncbi.nlm.nih.gov/pubmed/12644816
http://dx.doi.org/10.1038/sj.bjc.6600817

Ejemplares similares